NASDAQ:CRSP

CRISPR Therapeutics (CRSP) Price Target & Analyst Ratings

$64.04

-0.59 (-0.91%)

(As of 05/31/2023 ET)

Compare

Today's Range: $63.02
▼
$67.26
50-Day Range: $43.14
▼
$67.77
52-Week Range: $38.94
▼
$86.95

Volume: 1.32 million shs
Average Volume: 1.22 million shs
Market Capitalization: $5.05 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $74.89

CRISPR Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 19 Analyst Ratings

Consensus Analyst Price Target

$74.89
16.95% Upside

High Prediction	$123.00
Average Prediction	$74.89
Low Prediction	$39.00

Type	Current 6/1/22 to 6/1/23	1 Month Ago 5/2/22 to 5/2/23	3 Months Ago 3/3/22 to 3/3/23	1 Year Ago 6/1/21 to 6/1/22
Consensus Rating	Moderate Buy	Hold	Hold	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	10 Buy rating(s)	8 Buy rating(s)	9 Buy rating(s)
Hold	7 Hold rating(s)	8 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$74.89	$72.84	$77.33	$114.71
Predicted Upside	16.95% Upside	36.79% Upside	42.38% Upside	87.68% Upside

Get CRISPR Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

CRSP Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CRSP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CRISPR Therapeutics Stock vs. The Competition

Type	CRISPR Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.53	2.66	2.49
Consensus Rating	Moderate Buy	Buy	Hold
Predicted Upside	16.95% Upside	1,269.28% Upside	200.47% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Historical Target Prices and Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/30/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Corwin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00	+15.99%
5/23/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$55.00 ➝ $70.00	+6.38%
5/9/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
5/9/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$69.00 ➝ $64.00	+14.37%
4/20/2023	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$82.00	+53.33%
4/17/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$75.00	+38.63%

4/17/2023	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Outperform	$70.00	+29.39%
4/13/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	O. Brayer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$72.00	+65.63%
3/21/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$44.00	-1.03%
3/17/2023	Bryan, Garnier & Co Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$70.00	+54.22%
3/6/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$46.00	-6.75%
2/27/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underweight	$37.00 ➝ $39.00	-20.67%
2/23/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$110.00 ➝ $102.00	+102.46%
2/22/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$78.00 ➝ $65.00	+39.40%
2/22/2023	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$153.00 ➝ $123.00	+163.78%
11/7/2022	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$75.00 ➝ $76.00	+48.50%
11/2/2022	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sector Perform	$79.00 ➝ $70.00	+34.56%
11/2/2022	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$88.00 ➝ $61.00	+17.26%
6/22/2022	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$115.00 ➝ $121.00	+87.10%
6/16/2022	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$98.00	+51.59%

(Data available from 6/1/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

CRSP Price Target - Frequently Asked Questions

What is CRISPR Therapeutics's consensus rating and price target?: According to the issued ratings of 19 analysts in the last year, the consensus rating for CRISPR Therapeutics stock is Moderate Buy based on the current 1 sell rating, 7 hold ratings and 11 buy ratings for CRSP. The average twelve-month price prediction for CRISPR Therapeutics is $74.89 with a high price target of $123.00 and a low price target of $39.00. Learn more on CRSP's analyst rating history.
Do Wall Street analysts like CRISPR Therapeutics more than its competitors?: Analysts like CRISPR Therapeutics less than other Medical companies. The consensus rating for CRISPR Therapeutics is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how CRSP compares to other companies.
Does CRISPR Therapeutics's stock price have much upside?: According to analysts, CRISPR Therapeutics's stock has a predicted upside of 39.09% based on their 12-month price targets.

What analysts cover CRISPR Therapeutics?: CRISPR Therapeutics has been rated by Bryan, Garnier & Co, Cantor Fitzgerald, Citigroup, EF Hutton Acquisition Co. I, JMP Securities, Needham & Company LLC, Robert W. Baird, Sanford C. Bernstein, Stifel Nicolaus, VNET Group, and William Blair in the past 90 days.

Stock Ratings Reports and Tools

This page (NASDAQ:CRSP) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial